Kraj: Kanada
Język: angielski
Źródło: Health Canada
PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE)
ANGITA PHARMA INC.
A02BC02
PANTOPRAZOLE
40MG
TABLET (DELAYED-RELEASE)
PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 40MG
ORAL
15G/50G
Prescription
PROTON-PUMP INHIBITORS
Active ingredient group (AIG) number: 0133229001; AHFS:
APPROVED
2018-10-11
AG-PANTOPRAZOLE SODIUM Page 1 of 46 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR AG-PANTOPRAZOLE SODIUM Pantoprazole Sodium Delayed-Release Tablets Delayed-Release Tablet, 20 mg and 40 mg pantoprazole (as pantoprazole sodium sesquihydrate), Oral USP Proton Pump Inhibitor Angita Pharma Inc 1310 rue Nobel Boucherville, Quebec J4B 5H3, Canada Date of Initial Authorization: October 11, 2018 Date of Revision: September 27, 2023 Submission Control Number: 273071 AG-PANTOPRAZOLE SODIUM Page 2 of 46 RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, Endocrine and Metabolism 09/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics (< 18 years of age) .................................................................................. 4 1.2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.1 Dosing Considerations ............................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment ....................................................... 5 4.4 Administration ....................................................................................................... 6 4.5 Missed Przeczytaj cały dokument